|
1
|
Wang J, Shen Y, Sheng X, Yu H, Song M, Wang Q, Gu H. Unravelling Glucoraphanin and Glucoerucin Metabolism across Broccoli Sprout Development: Insights from Metabolite and Transcriptome Analysis. Plants (Basel) 2024; 13:750. [PMID: 38592746 PMCID: PMC10976094 DOI: 10.3390/plants13060750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 02/26/2024] [Accepted: 02/27/2024] [Indexed: 04/10/2024]
Abstract
Variations in the concentration of glucoraphanin (GRA) and glucoerucin (GER), as well as the corresponding breakdown products, isothiocyanates (ITCs) and nitriles, were investigated during the growth of broccoli sprouts. The concentrations of GRA and GER decreased sharply from 33.66 µmol/g to 11.48 µmol/g and 12.98 µmol/g to 8.23 µmol/g, respectively, after seed germination. From the third to the seventh day, both GRA and GER were maintained as relatively stable. The highest concentrations of sulforaphane (17.16 µmol/g) and erucin (12.26 µmol/g) were observed on the first day. Hereafter, the concentrations of nitrile hydrolyzed from GRA or GER were higher than those of the corresponding ITCs. Moreover, the ratio of sulforaphane to sulforaphane nitrile decreased from 1.35 to 0.164 from 1 d to 5 d, with a similar trend exhibited for erucin/erucin nitrile after 2 d. RNA-seq analysis showed that BolMYB28 and BolCYP83A1, involved in aliphatic glucosinolate (GSL) biosynthesis, remained largely unexpressed until the third day. In contrast, the genes operating within the GSL-myrosinase hydrolysis pathway were highly expressed right from the beginning, with their expression levels increasing significantly after the third day. Additionally, we identified two BolESPs and six BolNSPs that might play important roles in promoting the production of nitriles during the development of broccoli sprouts.
Collapse
Affiliation(s)
- Jiansheng Wang
- Institute of Vegetables, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.W.); (Y.S.); (X.S.); (H.Y.); (M.S.)
| | - Yusen Shen
- Institute of Vegetables, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.W.); (Y.S.); (X.S.); (H.Y.); (M.S.)
| | - Xiaoguang Sheng
- Institute of Vegetables, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.W.); (Y.S.); (X.S.); (H.Y.); (M.S.)
| | - Huifang Yu
- Institute of Vegetables, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.W.); (Y.S.); (X.S.); (H.Y.); (M.S.)
| | - Mengfei Song
- Institute of Vegetables, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.W.); (Y.S.); (X.S.); (H.Y.); (M.S.)
| | - Qiaomei Wang
- Key Laboratory of Horticultural Plant Growth, Development and Quality Improvement, Department of Horticulture, Zhejiang University, Hangzhou 310058, China;
| | - Honghui Gu
- Institute of Vegetables, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China; (J.W.); (Y.S.); (X.S.); (H.Y.); (M.S.)
| |
Collapse
|
|
2
|
Fields NJ, Palmer KR, Rolnik DL, Yo J, Nold MF, Giles ML, Krishnaswamy S, Serpa Neto A, Hodges RJ, Marshall SA. CO-Sprout-A Pilot Double-Blinded Placebo-Controlled Randomised Trial of Broccoli Sprout Powder Supplementation for Pregnant Women with COVID-19 on the Duration of COVID-19-Associated Symptoms: Study Protocol. Nutrients 2023; 15:3980. [PMID: 37764764 PMCID: PMC10537772 DOI: 10.3390/nu15183980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Revised: 09/08/2023] [Accepted: 09/13/2023] [Indexed: 09/29/2023] Open
Abstract
Since its discovery in late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been estimated to be responsible for at least 769.3 million infections and over 6.95 million deaths. Despite significant global vaccination efforts, there are limited therapies that are considered safe and effective for use in the management of COVID-19 during pregnancy despite the common knowledge that pregnant patients have a much higher risk of adverse outcomes. A bioactive compound found in broccoli sprout-sulforaphane-is a potent inducer of phase-II detoxification enzymes promoting a series of potentially beneficial effects notably as an antioxidant, anti-inflammatory, and anti-viral. A pilot, double-blinded, placebo-controlled randomised trial is to be conducted in Melbourne, Australia, across both public and private hospital sectors. We will assess a commercially available broccoli sprout extract in pregnant women between 20+0 and 36+0 weeks gestation with SARS-CoV-2 infection to investigate (i) the duration of COVID-19 associated symptoms, (ii) maternal and neonatal outcomes, and (iii) biomarkers of infection and inflammation. We plan to enrol 60 outpatient women with COVID-19 irrespective of vaccination status diagnosed by PCR swab or RAT (rapid antigen test) within five days and randomised to 14 days of oral broccoli sprout extract (42 mg of sulforaphane daily) or identical microcrystalline cellulose placebo. The primary outcome of this pilot trial will be to assess the feasibility of conducting a larger trial investigating the duration (days) of COVID-19-associated symptoms using a broccoli sprout supplement for COVID-19-affected pregnancies. Pregnant patients remain an at-risk group for severe disease following infection with SARS-CoV-2 and currently unclear consequences for the offspring. Therefore, this study will assess feasibility of using a broccoli sprout supplement, whilst providing important safety data for the use of sulforaphane in pregnancy.
Collapse
Affiliation(s)
- Neville J. Fields
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne 3168, Australia (D.L.R.); (M.F.N.); (M.L.G.); (R.J.H.); (S.A.M.)
- Monash Health, Monash Medical Centre, Melbourne 3168, Australia
| | - Kirsten R. Palmer
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne 3168, Australia (D.L.R.); (M.F.N.); (M.L.G.); (R.J.H.); (S.A.M.)
- Monash Health, Monash Medical Centre, Melbourne 3168, Australia
| | - Daniel L. Rolnik
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne 3168, Australia (D.L.R.); (M.F.N.); (M.L.G.); (R.J.H.); (S.A.M.)
- Monash Health, Monash Medical Centre, Melbourne 3168, Australia
| | - Jennifer Yo
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne 3168, Australia (D.L.R.); (M.F.N.); (M.L.G.); (R.J.H.); (S.A.M.)
- Monash Health, Monash Medical Centre, Melbourne 3168, Australia
| | - Marcel F. Nold
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne 3168, Australia (D.L.R.); (M.F.N.); (M.L.G.); (R.J.H.); (S.A.M.)
- Department of Paediatrics, Monash University, Melbourne 3168, Australia
- Monash Newborn, Monash Children’s Hospital, Melbourne 3168, Australia
| | - Michelle L. Giles
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne 3168, Australia (D.L.R.); (M.F.N.); (M.L.G.); (R.J.H.); (S.A.M.)
- Monash Health, Monash Medical Centre, Melbourne 3168, Australia
| | | | - Ary Serpa Neto
- Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Melbourne 3004, Australia;
- Department of Critical Care, Melbourne Medical School, University of Melbourne, Austin Hospital, Melbourne 3084, Australia
- Department of Intensive Care, Austin Hospital, Melbourne 3084, Australia
- Department of Critical Care Medicine, Hospital Israelita Albert Einstein, Sao Paulo 05652-900, Brazil
| | - Ryan J. Hodges
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne 3168, Australia (D.L.R.); (M.F.N.); (M.L.G.); (R.J.H.); (S.A.M.)
- Monash Health, Monash Medical Centre, Melbourne 3168, Australia
| | - Sarah A. Marshall
- The Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne 3168, Australia (D.L.R.); (M.F.N.); (M.L.G.); (R.J.H.); (S.A.M.)
| |
Collapse
|
|
3
|
Yusin J, Wang V, Henning SM, Yang J, Tseng CH, Thames G, Arnold I, Heber D, Lee RP, Sanavio L, Pan Y, Qin T, Li Z. The Effect of Broccoli Sprout Extract on Seasonal Grass Pollen-Induced Allergic Rhinitis. Nutrients 2021; 13:nu13041337. [PMID: 33920642 PMCID: PMC8074067 DOI: 10.3390/nu13041337] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2021] [Revised: 03/26/2021] [Accepted: 04/15/2021] [Indexed: 12/15/2022] Open
Abstract
Patients exposed to pollutants are more likely to suffer from allergic rhinitis and may benefit from antioxidant treatment. Our study determined if patients diagnosed with grass-induced allergic rhinitis could benefit from broccoli sprout extract (BSE) supplementation. In total, 47 patients were confirmed with grass-induced allergic rhinitis and randomized to one of four groups: group 1 (nasal steroid spray + BSE), group 2 (nasal steroid spray + placebo tablet), group 3 (saline nasal spray + BSE) and group 4 (saline nasal spray + placebo tablet). Peak Nasal Inspiratory Flow (PNIF), Total Nasal Symptoms Scores (TNSS) and nasal mucus cytokine levels were analyzed in samples collected before and after the 3-week intervention. Comparing before and after the intervention, PNIF improved significantly when comparing Groups 1 and 2, vs. placebo, at various time points (p ≤ 0.05 at 5, 15, 60 and 240 min) following nasal challenge, while TNSS was only statistically significant at 5 (p = 0.03), 15 (p = 0.057) and 30 (p = 0.05) minutes. There were no statistically significant differences in various cytokine markers before and after the intervention. Combining nasal corticosteroid with BSE led to the most significant improvement in objective measures.
Collapse
Affiliation(s)
- Joseph Yusin
- Department of Allergy and Immunology, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA; (V.W.); (G.T.); (I.A.); (Z.L.)
- Correspondence: ; Tel.: +1-310-478-3711 (ext. 40230); Fax: +1-310-268-4712
| | - Vivian Wang
- Department of Allergy and Immunology, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA; (V.W.); (G.T.); (I.A.); (Z.L.)
| | - Susanne M. Henning
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - Jieping Yang
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - Chi-Hong Tseng
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - Gail Thames
- Department of Allergy and Immunology, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA; (V.W.); (G.T.); (I.A.); (Z.L.)
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - Irina Arnold
- Department of Allergy and Immunology, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA; (V.W.); (G.T.); (I.A.); (Z.L.)
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - David Heber
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - Ru-Po Lee
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - Laura Sanavio
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - Yajing Pan
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - Tianyu Qin
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| | - Zhaoping Li
- Department of Allergy and Immunology, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA; (V.W.); (G.T.); (I.A.); (Z.L.)
- Department of Internal Medicine, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA; (S.M.H.); (J.Y.); (C.-H.T.); (D.H.); (R.-P.L.); (L.S.); (Y.P.); (T.Q.)
| |
Collapse
|
|
4
|
Langston-Cox AG, Marshall SA, Palmer KR, Wallace EM. Prolong: a double-blind randomised placebo-controlled trial of broccoli sprout extract in women with early onset preeclampsia. A clinical trial protocol. BMJ Open 2019; 9:e027493. [PMID: 31628121 PMCID: PMC6803158 DOI: 10.1136/bmjopen-2018-027493] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
INTRODUCTION Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality. There is a need for adjuvant, targeted therapies to improve outcomes. Broccoli sprout extract, rich in the antioxidant sulforaphane, reduces oxidative stress and placental secretion of the antiangiogenic factors that contribute to vascular dysfunction in preeclampsia. We propose a phase III trial investigating broccoli sprout extract. We will assess broccoli sprout extract in women with early onset (<34 weeks) preeclampsia, investigating (1) the interval between enrolment and delivery (days), (2) biomarkers of placental and endothelial function and (3) maternal and fetal outcomes. METHODS A double-blind, placebo-controlled randomised trial will be conducted at Monash Health, Melbourne, Australia. One hundred and eighty women (45 each arm of each stratum) with early onset preeclampsia (defined as per Society for Obstetric Medicine of Australia and New Zealand guidelines) will be recruited. Consenting women will be randomised to receive an oral dose of either broccoli sprout extract (24 mg of activated sulforaphane) or identical placebo, twice daily until delivery. Maternal blood will be collected antenatally for measurement of biomarkers of preeclampsia, including soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PlGF), soluble endoglin (sEng) and activin A, as well as circulating sulforaphane metabolites. Maternal and perinatal outcomes will be monitored throughout. All clinical care decisions, including the timing of delivery, will be made by the treating team, blinded to treatment allocation. Participation in this trial will not affect routine care. At delivery, maternal and cord blood and placentae will be collected to measure sulforaphane metabolites and sFlt-1, PlGF, sEng and activin A. ETHICS AND DISSEMINATION Approval to conduct the trial has been granted by Monash Health Human Research and Ethics Committee (RES-18-0000-109A). Deidentified data will be published in peer-reviewed journals and presented at learnt society conferences, both nationally and internationally. This study has not yet commenced and is pre-results.Trial registration numberACTRN12618000216213.
Collapse
Affiliation(s)
- Annie G Langston-Cox
- Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia
- The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia
| | - Sarah A Marshall
- Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia
- The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia
| | - Kirsten R Palmer
- Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia
- Monash Women's, Monash Health, Clayton, Victoria, Australia
| | - Euan M Wallace
- Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia
- The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia
| |
Collapse
|
|
5
|
Abstract
Cruciferous vegetables are widely acknowledged to provide chemopreventive benefits in humans, but they are not generally consumed at levels that effect significant change in biomarkers of health. Because consumers have embraced the notion that dietary supplements may prevent disease, this review considers whether an appropriately validated sulforaphane-yielding broccoli sprout supplement may deliver clinical benefit. The crucifer-derived bioactive phytochemical sulforaphane is a significant inducer of nuclear factor erythroid 2-related factor 2 (Nrf2), the transcription factor that activates the cell's endogenous defenses via a battery of cytoprotective genes. For a broccoli sprout supplement to demonstrate bioactivity in vivo, it must retain both the sulforaphane-yielding precursor compound, glucoraphanin, and the activity of glucoraphanin's intrinsic myrosinase enzyme. Many broccoli sprout supplements are myrosinase inactive, but current labeling does not reflect this. For the benefit of clinicians and consumers, this review summarizes the findings of in vitro studies and clinical trials, interpreting them in the context of clinical relevance. Standardization of sulforaphane nomenclature and assay protocols will be necessary to remove inconsistency and ambiguity in the labeling of currently available broccoli sprout products.
Collapse
Affiliation(s)
- Christine A Houghton
- School of Human Movement Studies, University of Queensland, Brisbane, Queensland, Australia
| | | | | |
Collapse
|